Eur J Hosp Pharm 19:550-551 doi:10.1136/ejhpharm-2012-000211
  • EMA new drug

EMA approved new drugs: ipilimumab (Yervoy) for the treatment of malignant melanoma

  1. Mark Nolan
  1. Correspondence to Mark Nolan, PharmD, 246 Winslow Way Apt 201, Bainbridge Is, WA 98110, USA; friendofpills{at}

Even though most cases of malignant melanoma are diagnosed early and treated surgically, there are individuals whose condition will progress to more severe stages of the disease and require systemic treatment. Previously, if a patient failed surgical treatment, they could be treated with dacarbazine as the chemotherapeutic agent of choice. Recently, treatment options have expanded to include immunotherapy with high dose interleukin 2, ipilimumab and vemurafenib. The best treatment regimens are still being filtered out, but current recommendations are to individualise treatment based on several factors, such as skin type, extent of disease and location, which are used in determining the overall condition of the patient and severity of the disease.

Although widely used in the treatment of malignant melanoma, chemotherapy has not been shown to improve overall survival, leaving clinicians and patients looking for more effective and less toxic treatments. Interleukin 2 can provide long term disease free survival in a small number of people but can cause a severe toxic reaction in multiple organs, limiting its widespread use. Vemurafenib is another new agent on the market and has shown an increase in survival, but only in those patients whose tumour contains a V600 mutation in the BRAF gene. Those individuals …

EJHP blog

Analysis and discussion of the latest news, research findings and policy developments in hospital pharmacy.

Visit the blog >>

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EJHP.

View free sample issue >>

Email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article